The biotech firm reported a wider-than-expected GAAP loss for Q2, with cash reserves nearly halving since year-end 2025.
Tvardi Therapeutics posted a Q2 GAAP loss per share of $0.69, missing estimates by $0.06. The wider-than-expected loss highlights ongoing financial pressure as the company advances its pipeline.
Cash and short-term investments fell to $15.8 million as of June 30, 2026, down from $30.8 million at the end of 2025. The decline underscores liquidity concerns amid ongoing operational costs.
The company did not disclose immediate market reaction, but the earnings miss and shrinking cash reserves may weigh on investor sentiment.